354 related articles for article (PubMed ID: 28279893)
1. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.
Rhee SJ; Shin JW; Lee S; Moon J; Kim TJ; Jung KY; Park KI; Lee ST; Jung KH; Yu KS; Jang IJ; Chu K; Lee SK
Epilepsy Res; 2017 May; 132():8-14. PubMed ID: 28279893
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of levetiracetam in neonates with seizures.
Lima-Rogel V; López-López EJ; Medellín-Garibay SE; Gómez-Ruiz LM; Romero-Méndez C; Milán-Segovia RC; Romano-Moreno S
J Clin Pharm Ther; 2018 Jun; 43(3):422-429. PubMed ID: 29265480
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data.
Ito S; Yano I; Hashi S; Tsuda M; Sugimoto M; Yonezawa A; Ikeda A; Matsubara K
Ther Drug Monit; 2016 Jun; 38(3):371-8. PubMed ID: 26913593
[TBL] [Abstract][Full Text] [Related]
7. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
8. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Auriel E; Chistik V; Blatt I; Margolin N; Neufeld M
Harefuah; 2007 Apr; 146(4):269-71, 318. PubMed ID: 17476932
[TBL] [Abstract][Full Text] [Related]
10. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.
Hirsch LJ; Arif H; Buchsbaum R; Weintraub D; Lee J; Chang JT; Resor SR; Bazil CW
Epilepsia; 2007 Jul; 48(7):1351-9. PubMed ID: 17573925
[TBL] [Abstract][Full Text] [Related]
11. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
Stephen LJ; Kelly K; Parker P; Brodie MJ
Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
[TBL] [Abstract][Full Text] [Related]
12. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
Stepanova D; Beran RG
Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Ben-Menachem E; Gilland E
Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy.
Giroux PC; Salas-Prato M; Théorêt Y; Carmant L
Seizure; 2009 Oct; 18(8):559-63. PubMed ID: 19546014
[TBL] [Abstract][Full Text] [Related]
15. Rapid onset of action of levetiracetam in refractory epilepsy patients.
French J; Arrigo C
Epilepsia; 2005 Feb; 46(2):324-6. PubMed ID: 15679515
[TBL] [Abstract][Full Text] [Related]
16. Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting.
Reimers A; Olsson P; Nilsson J; Hoff E; Reis M; Strandberg M; Lundgren A; Källén K
Epilepsy Res; 2017 Aug; 134():54-61. PubMed ID: 28595756
[TBL] [Abstract][Full Text] [Related]
17. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.
Toublanc N; Sargentini-Maier ML; Lacroix B; Jacqmin P; Stockis A
Clin Pharmacokinet; 2008; 47(5):333-41. PubMed ID: 18399714
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam monotherapy for elderly patients with epilepsy.
Alsaadi TM; Koopmans S; Apperson M; Farias S
Seizure; 2004 Jan; 13(1):58-60. PubMed ID: 14741184
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of long-term low-dose levetiracetam treatment for epilepsy.
Yoshikawa S; Shimakawa S; Fukui M; Nomura S; Tanabe T; Tamai H
Pediatr Int; 2016 Jan; 58(1):40-4. PubMed ID: 26189956
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy.
Kanemura H; Sano F; Tando T; Sugita K; Aihara M
Brain Dev; 2013 May; 35(5):386-91. PubMed ID: 22871391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
